Laboratory Products

  • ADC Service to Accelerate Pre-clinical Conjugation Candidate Selection Announced

ADC Service to Accelerate Pre-clinical Conjugation Candidate Selection Announced

Oct 09 2019 Read 306 Times

Merck has introduced its ADC Express TM services for the rapid production of ADCs, which can reduce the time needed to produce development grade constructs for target molecule identification. With more than 70% of ADC projects outsourced to CDMOs, this crucial and streamlined service enhances Merck’s offering of process development, analytical development, testing services and manufacturing or supply of linkers, cytotoxins/payloads and conjugates.
 
Merck is committed to working with ADC innovators to speed the delivery of potential new cancer treatments to patients. The company has been at the forefront of ADC manufacturing for the last decade and is one of the few CDMOs offering pre-clinical ADC development and other development and GMP services globally.
 
Merck’s established platform technology can efficiently turn an antibody, linker and payload into an ADC. The company offers a platform approach to ADC constructs and bioconjugation, resulting in increased flexibility and speed. 
 
ADC ExpressTM services include: mini-prep scale - 10–20 mg ADC construct ± column purification; medium-prep scale - ~100 mg ADC ± column purification; certificate of testing with key quality attributes, including ADC concentration, payload density/DAR (drug antibody ratio) and monomer/aggregate content and free residual payload.
 
For companies that have a rich pipeline of monoclonal antibodies (mAbs) and want to enter the ADC space, Merck’s ADC Express TM services allow them to obtain ADCs without having to invest in potent handling capabilities. Companies can either bring their own linker technology or procure a linker payload from Merck.
 
Traditionally, several CDMOs across the globe were involved in the development and production of ADC programs. Merck’s comprehensive ADC service portfolio combines the crucial steps of drug development and production: mAb solutions, linker, payload and the final conjugation - all from a single source. 
 
Merck has more than 35 years’ experience handling biological molecules and small molecules (including highly active or potent molecules), performing conjugation and complex analytical testing and manufacturing, reducing complexity for customers. 

More information online

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment




Digital Edition

LabAsia Buyers Guide 2019

October 2019

In This Edition Chromatography - Vacuum Ultraviolet Spectroscopy: A Versatile Tool for Analysis of Gasoline and Jet Fuels - High-performance Columns and Bulk for your Chromatography - New L...

View all digital editions

Events

Filtech

Oct 22 2019 Cologne, Germany

Chem Show 2019

Oct 22 2019 New York, USA

BCEIA 2019

Oct 23 2019 Beijing, China

Lab Innovations 2019

Oct 30 2019 Birmingham, UK

SETAC North America

Nov 03 2019 Toronto, Canada

View all events